

What is claimed is:

1. Bispecific antibodies which recognize both a) an antigen of predetermined macrophages, and b) an antigen of a tumoral cell to be targeted by said predetermined macrophages, wherein said predetermined macrophages have at least one of the following properties:

- their cytotoxic activity without IFN- γ is increased by about 20 to 30% with respect to standard macrophages;

- their cytotoxic activity with IFN- γ is increased by about 20 to about 40% with respect to standard macrophages;

- deactivation of the cytotoxic activity following activation of IFN- γ is such that sixty hours after activation with IFN- γ , the residual cytotoxic activity is at least 30% of the maximum cytotoxic activity presented by the macrophages due to IFN- γ activation, with said cytotoxic activity being measured as a percentage of the inhibition of 3-H thymidine incorporation by target tumoral cells, particularly U 937 cells.

2. A method for treating cancer, comprising - administering to a patient in need of said treatment an effective amount of the bispecific antibodies according to claim 1.